Loading...
Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $114.0K Total Trade · DGFT Verified
G P Interglobe is an Indian pharmaceutical exporter with a total trade value of $114.0K across 2 products in 1 therapeutic categories. Based on 14 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Pembrolizumab ($59.9K), Daratumumab ($54.0K), .
G P Interglobe is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2013, the company is headquartered at 464, Udyog Vihar, Phase V, Gurugram, Haryana, India. It operates as a partnership firm under the Goods and Services Tax Network (GSTN) with the registration number 06AAMFG4678E1Z6. The company has a Legal Entity Identifier (LEI) of 335800LTLJXNN62SB351, indicating its active status in global financial markets. G P Interglobe's export activities are primarily focused on the advanced oncology therapeutic category, with a total export value of $114,000 USD across 14 shipments. The company's product portfolio is highly concentrated, with its top two products—Pembrolizumab and Daratumumab—accounting for 100% of its exports.
G P Interglobe operates across 1 therapeutic categories, with Advanced Oncology (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Advanced Oncology
2 products · 100.0% · $114.0K
G P Interglobe exports 2 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Pembrolizumab | Advanced Oncology | $59.9K | 6 | 3.1% | 9 |
| 2 | Daratumumab |
Headquarters, ownership, manufacturing facilities, and key leadership
G P Interglobe is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2013, the company is headquartered at 464, Udyog Vihar, Phase V, Gurugram, Haryana, India. It operates as a partnership firm under the Goods and Services Tax Network (GSTN) with the registration number 06AAMFG4678E1Z6. The company has a Legal Entity Identifier (LEI) of 335800LTLJXNN62SB351, indicating its active status in global financial markets. G P Interglobe's export activities are primarily focused on the advanced oncology therapeutic category, with a total export value of $114,000 USD across 14 shipments. The company's product portfolio is highly concentrated, with its top two products—Pembrolizumab and Daratumumab—accounting for 100% of its exports.
Specific details regarding G P Interglobe's manufacturing facilities, including their locations, capacities, and specializations, are not publicly available. The company's export data indicates a focus on advanced oncology formulations, suggesting that its manufacturing operations are likely tailored to produce specialized oncology drugs. However, without explicit information, a comprehensive assessment of their manufacturing capabilities cannot be provided.
| $54.0K |
| 8 |
4.0% |
| 9 |
G P Interglobe exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $114.0K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Information about the key leadership of G P Interglobe, including the CEO, CFO, and other executives, is not publicly disclosed. The company's operations are managed by its partners, but specific names and roles are not available in the public domain. This lack of transparency makes it challenging to provide a detailed overview of the company's leadership structure.
Regulated market presence, emerging market penetration, and geographic strategy
G P Interglobe's export data indicates a focus on advanced oncology formulations, with Pembrolizumab and Daratumumab being its top two products. However, specific information regarding the company's regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. The absence of such data suggests that G P Interglobe may not have established a significant presence in these regulated markets. Without explicit information, a comprehensive analysis of the company's standing in these regions cannot be provided.
G P Interglobe's export data does not specify its activities in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on advanced oncology formulations suggests potential opportunities in these regions, especially considering the increasing demand for specialized cancer treatments. However, without explicit information on the company's WHO prequalification status or other certifications, it is difficult to assess its ability to access these markets.
G P Interglobe's export data reveals a highly concentrated product portfolio, with its top two products—Pembrolizumab and Daratumumab—accounting for 100% of its exports. This concentration indicates a focused geographic strategy, likely targeting markets with high demand for advanced oncology treatments. However, the lack of detailed information on the company's geographic diversification and market presence makes it challenging to assess potential concentration risks or strategic direction.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding G P Interglobe's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The absence of such data suggests that the company may not have established a significant presence in the U.S. market or may not have pursued FDA approvals for its products. Without explicit information, a comprehensive assessment of the company's FDA status cannot be provided.
Information regarding G P Interglobe's WHO prequalification status, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The lack of such certifications may limit the company's ability to access certain international markets that require these standards. However, without explicit information, it is difficult to assess the impact of this on the company's operations.
G P Interglobe operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. Without access to this information, a comprehensive assessment of the company's compliance with Indian regulatory requirements cannot be provided.
There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to G P Interglobe. The absence of such data suggests that the company may not have faced significant regulatory challenges in its operations. However, without explicit information, it is difficult to assess the company's overall regulatory compliance history.
Market share comparison, key differentiators, and strategic analysis
G P Interglobe's focus on advanced oncology formulations positions it in competition with other pharmaceutical companies specializing in oncology products. While specific market share data is not available, the company's export data indicates that Pembrolizumab and Daratumumab are its top two products, suggesting a competitive presence in the oncology market. However, without detailed information on competitors' offerings and market positions, a comprehensive competitive analysis cannot be provided.
G P Interglobe's specialization in advanced oncology formulations, particularly Pembrolizumab and Daratumumab, distinguishes it in the pharmaceutical export market. The company's focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs, indicates a commitment to delivering ready-to-use products. However, without detailed information on the company's manufacturing capabilities and certifications, it is challenging to identify additional unique strengths or competitive advantages.
G P Interglobe's strategic direction appears to be focused on exporting advanced oncology formulations, with a concentrated product portfolio centered around Pembrolizumab and Daratumumab. The company's lack of diversification in its product offerings suggests a niche strategy targeting specific markets with high demand for these treatments. However, without explicit information on the company's future outlook and plans for expansion or diversification, a comprehensive assessment of its strategic position cannot be provided.
Track record assessment, certifications to verify, and pre-order checks
G P Interglobe's export data indicates a total export value of $114,000 USD across 14 shipments, with a product portfolio entirely concentrated on Pembrolizumab and Daratumumab. This suggests a focused approach to its export activities. However, the lack of detailed information on the company's manufacturing facilities, certifications, and regulatory compliance makes it challenging to assess its overall track record, export volume consistency, and reliability as a supplier.
Importers considering G P Interglobe as a supplier should verify the following certifications to ensure product quality and regulatory compliance:
When considering G P Interglobe as a supplier, importers should undertake the following due diligence steps:
Red flags to watch for include a lack of transparency in operations, absence of necessary certifications, and inconsistent product quality. Recommended pre-order checks involve verifying the company's compliance with regulatory standards, assessing the reliability of its supply chain, and ensuring that the products meet the required specifications.
G P Interglobe exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Pembrolizumab ($59.9K), Daratumumab ($54.0K). Total export value is $114.0K.
G P Interglobe's total pharmaceutical export value is $114.0K, based on 14 verified shipments recorded in Indian Customs (DGFT) data.
G P Interglobe exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.